Could DAOIB slow memory loss? new trial begins

NCT ID NCT05582161

Recruiting now Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a drug called DAOIB in 123 people with mild Alzheimer's disease or mild cognitive impairment. Participants take DAOIB for 24 weeks, with dose adjustments every 8 weeks. Researchers will measure changes in thinking and memory, and look at blood markers related to brain stress. The goal is to see if these markers can predict how well the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DAOIB (a drug that may affect brain chemistry)
What this could lead to: If successful, this could point toward a new treatment option to slow cognitive decline in early Alzheimer's or mild cognitive impairment.
What could go wrong: This is a small, early-phase trial with no placebo group, so results may not prove effectiveness. The drug's long-term safety and benefits are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEMENTIA

Contacts and locations

Locations

Chang Gung Memorial Hospital
RECRUITING

Kaohsiung City, 886, Taiwan
China Medical University Hospital
RECRUITING

Taichung, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.